

Robert W Shafer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8384325/publications.pdf>

Version: 2024-02-01

91
papers

7,658
citations

87888

38
h-index

56724

83
g-index

96
all docs

96
docs citations

96
times ranked

7050
citing authors

#	ARTICLE	IF	CITATIONS
1	Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review. <i>Lancet Microbe</i> , The, 2022, 3, e392-e398.	7.3	14
2	Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system. <i>PLoS ONE</i> , 2022, 17, e0263742.	2.5	9
3	Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. <i>PLoS ONE</i> , 2022, 17, e0261045.	2.5	70
4	Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function. <i>Molecular Biology and Evolution</i> , 2022, 39, .	8.9	84
5	Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations. <i>Pathogens</i> , 2022, 11, 546.	2.8	3
6	Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	53
7	Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 736-743.	1.1	13
8	Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance. <i>Viruses</i> , 2021, 13, 879.	3.3	10
9	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	13.6	64
10	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	16.3	778
11	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021, 9, e0109621.	3.0	39
12	Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 170-182.	3.0	50
13	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. <i>Viruses</i> , 2020, 12, 1006.	3.3	60
14	Virological Failure and Acquired Genotypic Resistance Associated With Contemporary Antiretroviral Treatment Regimens. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa316.	0.9	8
15	HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates. <i>Journal of the International AIDS Society</i> , 2020, 23, e25611.	3.0	33
16	Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria. <i>AIDS Research and Therapy</i> , 2020, 17, 64.	1.7	5
17	Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations. <i>Viruses</i> , 2020, 12, 617.	3.3	40
18	Dry Panels Supporting External Quality Assessment Programs for Next Generation Sequencing-Based HIV Drug Resistance Testing. <i>Viruses</i> , 2020, 12, 666.	3.3	6

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women. <i>EClinicalMedicine</i> , 2020, 22, 100355.	7.1	5
20	Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. <i>PLoS ONE</i> , 2020, 15, e0225352.	2.5	20
21	Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2. <i>Journal of Infectious Diseases</i> , 2020, 221, 1962-1972.	4.0	14
22	A SARS-CoV-2 antiviral therapy score card. <i>Global Health & Medicine</i> , 2020, 2, 346-349.	1.4	0
23	Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. , 2020, 15, e0225352.		0
24	Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. , 2020, 15, e0225352.		0
25	Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. , 2020, 15, e0225352.		0
26	Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. , 2020, 15, e0225352.		0
27	Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population. <i>Clinical Infectious Diseases</i> , 2019, 68, 213-221.	5.8	46
28	Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Societyâ€“USA Panel. <i>Clinical Infectious Diseases</i> , 2019, 68, 177-187.	5.8	156
29	A systematic review of the genetic mechanisms of dolutegravir resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3135-3149.	3.0	95
30	Amino Acid Prevalence of HIV-1 <i>pol</i> Mutations by Direct Polymerase Chain Reaction and Single Genome Sequencing. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 924-929.	1.1	3
31	Prospective Evaluation of the Vela Diagnostics Next-Generation Sequencing Platform for HIV-1 Genotypic Resistance Testing. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 961-970.	2.8	17
32	Multiplex Solid-Phase Melt Curve Analysis for the Point-of-Care Detection of HIV-1 Drug Resistance. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 580-592.	2.8	8
33	National and International Dimensions of Human Immunodeficiency Virus-1 Sequence Clusters in a Northern California Clinical Cohort. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz135.	0.9	6
34	Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e246-e252.	9.1	41
35	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naïve Adults in South Africa, 2000â€“2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , 2019, 9, 26-34.	7.1	51
36	Reply to Ambrosioni et al. <i>Clinical Infectious Diseases</i> , 2019, 68, 1977-1978.	5.8	0

#	ARTICLE	IF	CITATIONS
37	P198â€¦Dolutegravir rollout and expected prevalence of pretreatment drug resistance to antiretroviral therapy among kenyan women. , 2019, , .		0
38	Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa. AIDS Research and Human Retroviruses, 2019, 35, 129-138.	1.1	21
39	The Clinical Implications of Pretreatment Drug Resistanceâ€”A Moving Target. Clinical Infectious Diseases, 2019, 69, 215-217.	5.8	3
40	2019 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 2019, 27, 111-121.	0.1	127
41	Comparison of an <i>In Vitro</i> Diagnostic Next-Generation Sequencing Assay with Sanger Sequencing for HIV-1 Genotypic Resistance Testing. Journal of Clinical Microbiology, 2018, 56, .	3.9	62
42	Diff-seq: A high throughput sequencing-based mismatch detection assay for DNA variant enrichment and discovery. Nucleic Acids Research, 2018, 46, e42-e42.	14.5	7
43	Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by their silicoapproach. Infection Ecology and Epidemiology, 2018, 8, 1528117.	0.8	5
44	Geographically-stratified HIV-1 group M pol subtype and circulating recombinant form sequences. Scientific Data, 2018, 5, 180148.	5.3	7
45	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine, 2017, 18, 225-235.	6.1	28
46	Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infectious Diseases, The, 2017, 17, 296-304.	9.1	58
47	Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update. Journal of Infectious Diseases, 2017, 216, S843-S846.	4.0	14
48	NucAmino: a nucleotide to amino acid alignment optimized for virus gene sequences. BMC Bioinformatics, 2017, 18, 138.	2.6	12
49	Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS ONE, 2017, 12, e0181357.	2.5	31
50	Genetic Variability of HIV-1 for Drug Resistance Assay Development. Viruses, 2016, 8, 48.	3.3	14
51	Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0158560.	2.5	35
52	Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC. Clinical Infectious Diseases, 2016, 63, 836-843.	5.8	37
53	HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. Journal of Virology, 2016, 90, 6058-6070.	3.4	72
54	Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility. AIDS Research and Human Retroviruses, 2016, 32, 702-704.	1.1	7

#	ARTICLE	IF	CITATIONS
55	HIV-1 drug resistance and resistance testing. <i>Infection, Genetics and Evolution</i> , 2016, 46, 292-307.	2.3	215
56	Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2597-2601.	3.9	16
57	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	9.1	217
58	Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. <i>Drugs</i> , 2016, 76, 75-98.	10.9	15
59	More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1. <i>ELife</i> , 2016, 5, .	6.0	70
60	2017 Update of the Drug Resistance Mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2016, 24, 132-133.	0.1	132
61	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810.	8.4	188
62	HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. <i>PLoS ONE</i> , 2015, 10, e0145772.	2.5	72
63	2015 Update of the Drug Resistance Mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2015, 23, 132-41.	0.1	103
64	Similar Prevalence of Low-Abundance Drug-Resistant Variants in Treatment-Naive Patients with Genotype 1a and 1b Hepatitis C Virus Infections as Determined by Ultradeep Pyrosequencing. <i>PLoS ONE</i> , 2014, 9, e105569.	2.5	18
65	A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. <i>Aids</i> , 2014, 28, F1-F8.	2.2	32
66	2014 Update of the drug resistance mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2014, 22, 642-50.	0.1	173
67	Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4290-4299.	3.2	23
68	Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens. <i>PLoS ONE</i> , 2013, 8, e67188.	2.5	59
69	Standardized Comparison of the Relative Impacts of HIV-1 Reverse Transcriptase (RT) Mutations on Nucleoside RT Inhibitor Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2305-2313.	3.2	48
70	The HIVdb System for HIV-1 Genotypic Resistance Interpretation. <i>Intervirology</i> , 2012, 55, 98-101.	2.8	124
71	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses, 2010, 2, 2696-2739.	3.3	35
72	HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4253-4261.	3.2	169

#	ARTICLE	IF	CITATIONS
73	Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE, 2009, 4, e4724.	2.5	823
74	Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms. Journal of Infectious Diseases, 2009, 200, 453-463.	4.0	39
75	Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2pheno on a Large Clinical Database. Journal of Infectious Diseases, 2009, 199, 999-1006.	4.0	40
76	HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Reviews, 2008, 10, 67-84.	1.0	218
77	HIV-1 Subtype B Protease and Reverse Transcriptase Amino Acid Covariation. PLoS Computational Biology, 2007, 3, e87.	3.2	92
78	HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. Aids, 2007, 21, 215-223.	2.2	277
79	Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation. Clinical Infectious Diseases, 2006, 42, 1608-1618.	5.8	545
80	Rationale and Uses of a Public HIV Drug-Resistance Database. Journal of Infectious Diseases, 2006, 194, S51-S58.	4.0	325
81	A COMBINED DATA MINING APPROACH FOR INFREQUENT EVENTS: ANALYZING HIV MUTATION CHANGES BASED ON TREATMENT HISTORY. , 2006, , .		3
82	Case files from Stanford University Medical Center: Drug resistance testing in previously untreated patients with HIV--knowing what to look for and choosing appropriate therapy. MedGenMed: Medscape General Medicine, 2006, 8, 32.	0.2	1
83	Drug resistance and antiretroviral drug development. Journal of Antimicrobial Chemotherapy, 2005, 55, 817-820.	3.0	21
84	Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research, 2003, 31, 298-303.	14.5	730
85	Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clinical Microbiology Reviews, 2002, 15, 247-277.	13.6	259
86	Rapid Communication: Efavirenz- and Adefovir Dipivoxil-Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic Response. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 221-226.	2.1	22
87	Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nature Medicine, 2000, 6, 1290-1292.	30.7	83
88	Rapid Communication: Efavirenz- and Adefovir Dipivoxil-Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic Response. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 221-226.	2.1	48
89	HIV Type 1 Envelope Subtype C Sequences from Recent Seroconverters in Zimbabwe. AIDS Research and Human Retroviruses, 2000, 16, 973-979.	1.1	35
90	The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Reviews, 2000, 2, 211-228.	1.0	32

#	ARTICLE	IF	CITATIONS
91	Editorial: New Virologic Tools for the Design and Analysis of Clinical Trials. Journal of Infectious Diseases, 1995, 171, 1325-1328.	4.0	6